The Claim
Semaglutide treatment in obese adults with type 2 diabetes is associated with increased secretion of gelsolin from epicardial fat, a protein with antithrombotic properties, suggesting a potential mechanism for reduced vascular clotting risk.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In obese adults with type 2 diabetes, semaglutide treatment is linked to higher levels of gelsolin protein released from fat tissue around the heart, and this protein is known to reduce blood clot formation.
See the scientific wording
Semaglutide treatment in obese adults with type 2 diabetes is associated with increased secretion of gelsolin from epicardial fat, a protein with antithrombotic properties, suggesting a potential mechanism for reduced vascular clotting risk.
Semaglutide activates a receptor on heart fat cells, causing them to release tiny packets filled with gelsolin protein. These packets travel to blood vessels, where gelsolin breaks down strands of actin that help form blood clots, making clots less stable and less likely to block arteries.
What the research says
1 studySemaglutide, a diabetes and weight-loss drug, makes the fat around the heart release more gelsolin — a protein that helps prevent dangerous blood clots. The study found this exact effect in patients taking the drug.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.